KIEO Statistics
Stats Compound: Molecular Info Compound: Selectivity Compound: Promiscuity FDA List
Overview
Kinases Data Points
0
0
Platforms (KPL) Series (KSE)
0
0
Samples (KSM) Unique Compounds
0
0
Series Collection
Data Sources
Moderate Threshold (POC < 15%, IC50/Kd/Ki < 1uM)
▶
●
RGC
●
CMGC
●
PI3K
●
TKL
●
Atypical
●
AGC
●
CAMK
●
Other
●
CK1
●
TK
●
STE
Full Name Receptor Guanylate Gyclases CDK, MAPK, GSK3 and CLK Phosphoinositide 3-kinase Tyrosine kinase-like Atypical Protein Kinase A, G, and C families Calmodulin/Calcium regulated kinases Other Casein Kinase 1 Tyrosine Kinase Homologs of the yeast STE7, STE11, and STE20 genes
# of Kinases 0 0 0 0 0 0 0 0 0 0 0
# of Compounds 0 0 0 0 0 0 0 0 0 0 0
Stringent Threshold (POC < 1%, IC50/Kd/Ki < 100nM)
▶
●
RGC
●
CMGC
●
PI3K
●
TKL
●
Atypical
●
AGC
●
CAMK
●
Other
●
CK1
●
TK
●
STE
Full Name Receptor Guanylate Gyclases CDK, MAPK, GSK3 and CLK Phosphoinositide 3-kinase Tyrosine kinase-like Atypical Protein Kinase A, G, and C families Calmodulin/Calcium regulated kinases Other Casein Kinase 1 Tyrosine Kinase Homologs of the yeast STE7, STE11, and STE20 genes
# of Kinases 0 0 0 0 0 0 0 0 0 0 0
# of Compounds 0 0 0 0 0 0 0 0 0 0 0
  • Promiscuity
    •
    Promiscuity
    Number of kinases Moderate Threshold: # Compounds Stringent Threshold: # Compounds


    ⚈ Moderate Threshold (POC < 15%, IC50/Kd/Ki < 1uM)
    ⚈ Stringent Threshold (POC < 1%, IC50/Kd/Ki < 100nM)
    FDA Approved Kinase Inhibitors
    DRUG FDA APPROVAL YEAR INTENDED TARGETS INDICATIONS*
     * Abbreviation : ALL, acute lymphoblastic leukemia, CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; CRC, colorectal cancer; DTC, differentiated thyroid carcinoma; GIST, gastrointestinal stromal tumor; NSCLC, non-small cell lung cancer; PV, polycythemia vera; RCC, renal cell carcinoma.
    Targets of FDA Approved Kinase Inhibitors